参考文献/References:
[1] Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
[2] Wang J,Yu F,Shang Y,et al.Thyroid cancer:Incidence and mortality trends in China,2005—2015[J].Endocrine,2020,68(1):163-173.
[3] Pizzato M,Li M,Vignat J,et al.The epidemiological landscape of thyroid cancer worldwide:GLOBOCAN estimates for incidence and mortality rates in 2020[J].Lancet Diabetes Endocrinol,2022,10(4):264-272.
[4] Siegel RL,Miller KD,Jemal A.Cancer statistics,2019[J].CA Cancer J Clin,2019,69(1):7-34.
[5] Haddad RI,Nasr C,Bischoff L,et al.Nccn guidelines insights:Thyroid carcinoma,version 2.2018[J].J Natl Compr Canc Netw,2018,16(12):1429-1440.
[6] Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
[7] Giuffrida D,Gharib H.Anaplastic thyroid carcinoma:Current diagnosis and treatment[J].Ann Oncol,2000,11(9):1083-1089.
[8] Fagin JA,Wells SA.Biologic and clinical perspectives on thyroid cancer[J].N Engl J Med,2016,375(23):2307.
[9] Deberardinis RJ,Cheng T.Q's next:The diverse functions of glutamine in metabolism,cell biology and cancer[J].Oncogene,2010,29(3):313-324.
[10] Hensley CT,Wasti AT,Deberardinis RJ.Glutamine and cancer:Cell biology,physiology,and clinical opportunities[J].J Clin Invest,2013,123(9):3678-3684.
[11] Wang C,Wu J,Wang Z,et al.Glutamine addiction activates polyglutamine-based nanocarriers delivering therapeutic siRNAs to orthotopic lung tumor mediated by glutamine transporter SLC1A5[J].Biomaterials,2018,183:77-92.
[12] Son J,Lyssiotis CA,Ying H,et al.Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway[J].Nature,2013,496(7443):101-105.
[13] Jin L,Alesi GN,Kang S.Glutaminolysis as a target for cancer therapy[J].Oncogene,2016,35(28):3619-3625.
[14] Yazawa T,Shimizu K,Kaira K,et al.Clinical significance of coexpression of L-type amino acid transporter 1(LAT1)and ASC amino acid transporter 2(ASCT2)in lung adenocarcinoma[J].Am J Transl Res,2015,7(6):1126-1139.
[15] Guo H,Xu Y,Wang F,et al.Clinical associations between ASCT2 and p-mTOR in the pathogenesis and prognosis of epithelial ovarian cancer[J].Oncol Rep,2018,40(6):3725-3733.
[16] Csanadi A,Oser A,Aumann K,et al.Overexpression of SLC1A5 in lymph node metastases outperforms assessment in the primary as a negative prognosticator in non-small cell lung cancer[J].Pathology,2018,50(3):269-275.
[17] Matés JM,Segura JA,Martín-Rufián M,et al.Glutaminase isoenzymes as key regulators in metabolic and oxidative stress against cancer[J].Curr Mol Med,2013,13(4):514-534.
[18] 林松荣,张 磊,罗金现,等.DNA甲基化修饰在甲状腺癌中的研究进展[J].陕西医学杂志,2021,50(2):254-257.
[19] 傅 强,黄学阳,王建春,等.养阴散结汤辅助治疗分化型甲状腺癌疗效及对患者术后甲状腺、免疫功能和血清学指标的影响[J].陕西中医,2022,43(8):1029-1031,1036.
[20] Abooshahab R,Gholami M,Sanoie M,et al.Advances in metabolomics of thyroid cancer diagnosis and metabolic regulation[J].Endocrine,2019,65(1):1-14.
[21] Curthoys NP,Watford M.Regulation of glutaminase activity and glutamine metabolism[J].Annu Rev Nutr,1995,15:133-159.
[22] Lane AN,Fan TW.Regulation of mammalian nucleotide metabolism and biosynthesis[J].Nucleic Acids Res,2015,43(4):2466-2485.
[23] Van-Geldermalsen M,Wang Q,Nagarajah R,et al.ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer[J].Oncogene,2016,35(24):3201-3208.
[24] Wang Q,Hardie RA,Hoy AJ,et al.Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development[J].J Pathol,2015,236(3):278-289.
[25] Esaki N,Ohkawa Y,Hashimoto N,et al.ASC amino acid transporter 2,defined by enzyme-mediated activation of radical sources,enhances malignancy of GD2-positive small-cell lung cancer[J].Cancer Sci,2018,109(1):141-153.
[26] Wang Q,Beaumont KA,Otte NJ,et al.Targeting glutamine transport to suppress melanoma cell growth[J].Int J Cancer,2014,135(5):1060-1071.
[27] 刘新艳,王媛媛,刘娜娜,等.谷氨酰胺代谢对人甲状腺癌细胞系体外增殖能力影响的实验研究[J].陕西医学杂志,2022,51(9):1153-1157.
相似文献/References:
[1]陈宏月,李兴江△.甲状腺全切除术对甲状腺癌患者血清血管内皮生长因子、可溶性Fas受体、可溶性Fas受体配体mRNA表达的影响研究[J].陕西医学杂志,2020,49(1):96.
CHEN Hongyue,LI Xingjiang..Effect of total thyroidectomy on mRNA expression levels of VEGF,sFas and sFasL in serum of patients with thyroid cancer[J].,2020,49(3):96.
[2]谢新静,李忠原.实时剪切波弹性成像联合甲状腺球蛋白抗体检测在甲状腺癌诊断中的应用研究[J].陕西医学杂志,2021,50(2):154.[doi:DOI:10.3969/j.issn.1000-7377.2021.02.007]
XIE Xinjing,LI Zhongyuan.Application of real-time shear wave elastography combined with Tg-Ab detection in diagnosis of thyroid cancer[J].,2021,50(3):154.[doi:DOI:10.3969/j.issn.1000-7377.2021.02.007]
[3]林松荣,张 磊,罗金现,等.DNA甲基化修饰在甲状腺癌中的研究进展[J].陕西医学杂志,2021,50(2):254.[doi:DOI:10.3969/j.issn.1000-7377.2021.02.033]
LIN Songrong,ZHANG Lei,LUO Jinxian,et al.Research progress of DNA methylation in thyroid cancer[J].,2021,50(3):254.[doi:DOI:10.3969/j.issn.1000-7377.2021.02.033]
[4]刘新艳,王媛媛,刘娜娜,等.谷氨酰胺代谢对人甲状腺癌细胞系体外增殖能力影响的实验研究[J].陕西医学杂志,2022,51(9):1153.[doi:DOI:10.3969/j.issn.1000-7377.2022.09.026]
LIU Xinyan,WANG Yuanyuan,LIU Nana,et al.Effects of glutamine metabolism on proliferation of human thyroid cancer cell lines in vitro[J].,2022,51(3):1153.[doi:DOI:10.3969/j.issn.1000-7377.2022.09.026]
[5]石维超,张少波.甲状腺癌病理微血管密度与颈部淋巴结转移相关性研究[J].陕西医学杂志,2022,51(11):1449.[doi:DOI:10.3969/j.issn.1000-7377.2022.11.031]
SHI Weichao,ZHANG Shaobo.Correlation between pathological microvessel density and cervical lymph node metastasis in thyroid cancer[J].,2022,51(3):1449.[doi:DOI:10.3969/j.issn.1000-7377.2022.11.031]